Measures · D12 in 2015 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Hypertension (RAS antagonists)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- One of the most important ways you can manage your health is by taking your medication as directed. The plan, the doctor, and the member can work together to find ways to help the member take their medication as directed. Percent of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.)
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 18 years or older that adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications]. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or over for RAS antagonist medications during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years or older with at least two fills of either the same medication or medications in the drug class during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. Patients are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Part D Medication Adherence measure is adapted from the Medication Adherence-Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). The PDC Adherence measures are also endorsed by the National Quality Forum (NQF). See the medication list for this measure. The Part D Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date methodology maintained by the PQA. The complete NDC list will be posted along with these technical notes. For the 2015 Star Ratings, NDCs with obsolete dates will be included in the measure calculation if their obsolete dates as reported by PQA are within the period of measurement (measurement year).
- Data source
- Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; The data for this measure come from PDE data files submitted by drug plans to Medicare for January 1, 2013-December 31, 2013 by June 30, 2014. Only final action PDE claims are used to calculate the patient safety measures. PDE claims are limited to members who received at least two prescriptions for RAS antagonist medication(s). PDE adjustments made post-reconciliation were not reflected in this measure.
- Measurement period
- 01/01/2013 - 12/31/2013
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Relative Distribution and Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- —
- Exclusions
Show
A percentage is not calculated for contracts with 30 or fewer beneficiary member years (in the denominator).- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, member-years of enrollment is the adjustment made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the spell level, and inclusion in the measure is determined separately for each spell – i.e., to be included for a given spell, the beneficiary must meet the initial inclusion criteria for the measure during that spell. The measure is weighted based on the total number of member years for each spell in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three month spell, disenrolled for a six month spell, reenrolled for a three month spell, and meets the measure criteria during each enrollment spell , s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA-PDs. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculations.
From the 2015 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 87 | 88 | +1 |
| 3★ | PDP | 89 | 90 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 92 | 92 | 0 |
2015 star distribution
Not rated: Plan too new to be measured (154); Plan not required to report measure (13); Not enough data available (10); No data available (4)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2026 | PDP | < 88 % | >= 88 % to < 90 % | >= 90 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2025 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2024 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 94 % | >= 94 % |
| 2023 | MA-PD | < 78 % | >= 78 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2023 | PDP | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 96 % | >= 96 % |
| 2022 | MA-PD | < 74 % | >= 74 % to < 82 % | >= 82 % to < 87 % | >= 87 % to < 90 % | >= 90 % |
| 2022 | PDP | < 85 % | >= 85 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2021 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % |
| 2021 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2020 | MA-PD | < 80% | ? 80% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2020 | PDP | < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% to < 90% | ? 90% |
| 2019 | MA-PD | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | PDP | < 84% | ? 84% to < 86% | ? 86% to < 87% | ? 87% to < 89% | ? 89% |
| 2018 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2018 | PDP | < 78% | ? 78% to < 83% | ? 83% to < 86% | ? 86% to < 89% | ? 89% |
| 2017 | MA-PD | < 71% | ? 71% to < 75% | ? 75% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 77% | ? 77% to < 80% | ? 80% to < 83% | ? 83% to < 85% | ? 85% |
| 2016 | MA-PD | < 58% | ? 58% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2016 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2015 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 85% | ? 85% |
| 2015 | PDP | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 84% | ? 84% |
Lowest-scoring contracts, 2015
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H9285 ATLANTIS HEALTH PLAN, INC. | America's 1st Choice NY Holdings, LLC | — | 62 | 1 | — | 19 | 0% |
| H0908 Wellcare | Centene Corporation | 8,453 | 62 | 1 | — | 19 | 0% |
| S2505 WINDSOR HEALTH PLAN, INC. | WellCare Health Plans, Inc. | — | 68 | 1 | — | 13 | 0% |
| H5887 MMM HEALTHCARE, INC. | InnovaCare Inc. | — | 62 | 1 | — | 19 | 0% |
| H0901 AETNA HEALTH, INC. (PA) | Aetna Inc. | — | 64 | 1 | — | 17 | 1% |
| H5430 WellCare | Centene Corporation | — | 64 | 1 | — | 17 | 1% |
| H3337 LIBERTY HEALTH ADVANTAGE, INC. | Liberty Health Advantage, Inc. | — | 66 | 1 | — | 15 | 1% |
| H5943 VillageHealth | SCAN Group | 649 | 66 | 1 | — | 15 | 1% |
| H5969 AlohaCare | AlohaCare | 2,637 | 66 | 1 | — | 15 | 1% |
| H2773 Quality Health Plans Of New York, Inc. | QHP Financial Group, Inc. | — | 66 | 1 | — | 15 | 1% |
| S7694 Elixir Insurance | Rite Aid Corporation | — | 69 | 1 | — | 12 | 2% |
| H0251 UnitedHealthcare | UnitedHealth Group, Inc. | 76,188 | 67 | 1 | — | 14 | 2% |
| H0490 Molina Healthcare Of Ohio, Inc. | Molina Healthcare, Inc., | — | 67 | 1 | — | 14 | 2% |
| H5774 Triple S Advantage | Guidewell Mutual Holding Corporation | 121,384 | 67 | 1 | — | 14 | 2% |
| H6972 HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. | CIGNA | — | 67 | 1 | — | 14 | 2% |
| H8189 Wellcare | Centene Corporation | 12,646 | 67 | 1 | — | 14 | 2% |
| H5640 IEHP HEALTH ACCESS | INLAND EMPIRE HEALTH PLAN | — | 67 | 1 | — | 14 | 2% |
| H4227 VISTA Health Plan Inc. | Independence Health Group, Inc. | 23,267 | 67 | 1 | — | 14 | 2% |
| H5294 Wellcare | Centene Corporation | 16,255 | 67 | 1 | — | 14 | 2% |
| H4011 MMM HEALTHCARE, LLC. | InnovaCare Inc. | — | 67 | 1 | — | 14 | 2% |
| H8130 Molina Healthcare of Florida | Molina Healthcare, Inc., | — | 67 | 1 | — | 14 | 2% |
| H1903 WELLCARE OF LOUISIANA, INC. | WellCare Health Plans, Inc. | — | 67 | 1 | — | 14 | 2% |
| S2874 Humana | Humana Inc. | — | 71 | 1 | — | 10 | 4% |
| H5698 WINDSOR HEALTH PLAN, INC. | WellCare Health Plans, Inc. | — | 68 | 1 | — | 13 | 4% |
| R9896 CARE IMPROVEMENT PLUS SOUTH CENTRAL INSURANCE CO. | UnitedHealth Group, Inc. | — | 68 | 1 | — | 13 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |